1
2
3
4
Bos, J.M., Rietveld, E., Moll, HA, Steyerberg, E.W., Luytjes, W., Wilschut, J.C., de Groot, R., Postma, M.J.
Veröffentlicht in: Bos , J M , Rietveld , E , Moll , HA , Steyerberg , E W , Luytjes , W , Wilschut , J C , de Groot , R & Postma , M J 2007 , ' The use of health economics to guide drug development decisions : Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach ' , Vaccine , vol. 25 , no. 39-40 , pp. 6922-6929 . https://doi.org/10.1016/j.vaccine.2007.07.006;
2007
Veröffentlicht in: Bos , J M , Rietveld , E , Moll , HA , Steyerberg , E W , Luytjes , W , Wilschut , J C , de Groot , R & Postma , M J 2007 , ' The use of health economics to guide drug development decisions : Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach ' , Vaccine , vol. 25 , no. 39-40 , pp. 6922-6929 . https://doi.org/10.1016/j.vaccine.2007.07.006;
2007
5
6
Meijboom, M. J., Rozenbaum, M. H., Benedictus, A., Luytjes, W., Kneyber, M. C. J., Wilschut, J. C., Hak, E., Postma, M. J.
Veröffentlicht in: Meijboom , M J , Rozenbaum , M H , Benedictus , A , Luytjes , W , Kneyber , M C J , Wilschut , J C , Hak , E & Postma , M J 2012 , ' Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands ' , Vaccine , vol. 30 , no. 31 , pp. 4691-4700 . https://doi.org/10.1016/j.vaccine.2012.04.072;
2012
Veröffentlicht in: Meijboom , M J , Rozenbaum , M H , Benedictus , A , Luytjes , W , Kneyber , M C J , Wilschut , J C , Hak , E & Postma , M J 2012 , ' Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands ' , Vaccine , vol. 30 , no. 31 , pp. 4691-4700 . https://doi.org/10.1016/j.vaccine.2012.04.072;
2012